Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Exact Sciences ( (EXAS) ) is now available.
Exact Sciences Corporation, a Delaware-based cancer diagnostics company, agreed on November 19, 2025, to be acquired by Abbott Laboratories through a merger in which a wholly owned Abbott subsidiary will merge into Exact, leaving Exact as a direct, wholly owned subsidiary of Abbott. On February 20, 2026, Exact’s stockholders approved the transaction, and by March 19, 2026, all required regulatory approvals had been secured, with the companies expecting to close the merger on March 23, 2026, pending satisfaction or waiver of remaining closing conditions.
The deal’s progression through shareholder and regulatory milestones signals a near-term change in Exact’s ownership structure, integrating its cancer diagnostics portfolio into Abbott’s larger healthcare platform. This anticipated closing marks a consolidation move in the diagnostics sector that could enhance Abbott’s position in cancer testing while bringing Exact’s operations and stakeholders under the umbrella of a global healthcare conglomerate.
The most recent analyst rating on (EXAS) stock is a Buy with a $114.00 price target. To see the full list of analyst forecasts on Exact Sciences stock, see the EXAS Stock Forecast page.
Spark’s Take on EXAS Stock
According to Spark, TipRanks’ AI Analyst, EXAS is a Neutral.
The score is supported primarily by improving fundamentals (stronger cash generation and solid margins) and a clearly positive technical trend. These positives are moderated by weak valuation metrics driven by ongoing losses and some merger-related legal/closing risk despite shareholder approval.
To see Spark’s full report on EXAS stock, click here.
More about Exact Sciences
Exact Sciences Corporation is a U.S.-based diagnostics company specializing in cancer screening and diagnostic tests. The company focuses on early detection technologies and has built a significant presence in the medical diagnostics market, positioning itself as a key player in cancer-related testing solutions.
Average Trading Volume: 2,233,600
Technical Sentiment Signal: Buy
Current Market Cap: $19.84B
For an in-depth examination of EXAS stock, go to TipRanks’ Overview page.